Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Cidara Therapeutics Q1 Earnings

Cidara Therapeutics (NASDAQ:CDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Cidara Therapeutics (NASDAQ:CDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

Cidara Therapeutics beat estimated earnings by 6.9%, reporting an EPS of $-0.27 versus an estimate of $-0.29.

Revenue was up $4.70 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.08 which was followed by a 1.75% increase in the share price the next day.

Here’s a look at Cidara Therapeutics’s past performance:

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.34 -0.36 -0.08 -0.31
EPS Actual -0.26 -0.37 0.18 -0.39
Revenue Estimate 4.31M 2.94M 18.20M 8.33M
Revenue Actual 7.22M 7.08M 32.86M 2.41M

To track all earnings releases for Cidara Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cango Shifts Gears Into Macro Headwinds, With Eye on NEVs and Car Services

Key Takeaways: Cango reported its fourth-quarter revenue rose sequentially but was down slightly from a year ago, as its newer car-trading services took up a larger portion of the total Company faces a number of macroeconomic headwinds, including pandemic restrictions and a chip shortage that has dampened new car sales worldwide By Doug Young

ATHM